152 related articles for article (PubMed ID: 6218370)
1. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma.
Delmas PD; Charhon S; Chapuy MC; Vignon E; Briancon D; Edouard C; Meunier PJ
Metab Bone Dis Relat Res; 1982; 4(3):163-8. PubMed ID: 6218370
[TBL] [Abstract][Full Text] [Related]
2. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.
Siris ES; Sherman WH; Baquiran DC; Schlatterer JP; Osserman EF; Canfield RE
N Engl J Med; 1980 Feb; 302(6):310-5. PubMed ID: 6444241
[TBL] [Abstract][Full Text] [Related]
3. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
Siris ES; Hyman GA; Canfield RE
Am J Med; 1983 Mar; 74(3):401-6. PubMed ID: 6219577
[TBL] [Abstract][Full Text] [Related]
4. Dichloromethylene diphosphonate action in hematologic and other malignancies.
Canfield RE; Siris ES; Jacobs TP
Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy.
Merlini G; Parrinello GA; Piccinini L; Crema F; Fiorentini ML; Riccardi A; Pavesi F; Novazzi F; Silingardi V; Ascari E
Hematol Oncol; 1990; 8(1):23-30. PubMed ID: 2137106
[TBL] [Abstract][Full Text] [Related]
6. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
Attardo-Parrinello G; Merlini G; Pavesi F; Crema F; Fiorentini ML; Ascari E
Arch Intern Med; 1987 Sep; 147(9):1629-33. PubMed ID: 2957971
[TBL] [Abstract][Full Text] [Related]
7. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma.
Paterson AD; Kanis JA; Cameron EC; Douglas DL; Beard DJ; Preston FE; Russell RG
Br J Haematol; 1983 May; 54(1):121-32. PubMed ID: 6221750
[TBL] [Abstract][Full Text] [Related]
8. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone.
Delmas PD; Chapuy MC; Vignon E; Charhon S; Briancon D; Alexandre C; Edouard C; Meunier PJ
J Clin Endocrinol Metab; 1982 Apr; 54(4):837-44. PubMed ID: 6460781
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.
Douglas DL; Duckworth T; Kanis JA; Preston C; Beard DJ; Smith TW; Underwood I; Woodhead JS; Russell RG
Arthritis Rheum; 1980 Oct; 23(10):1185-92. PubMed ID: 6448604
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical acute hypercalcemic effect of salmon calcitonin in patients having Paget's disease of bone after treatment with dichloromethylene diphosphonate.
Delmas PD; Chapuy MC; Meunier PJ
Horm Metab Res; 1984 May; 16(5):258-61. PubMed ID: 6234216
[TBL] [Abstract][Full Text] [Related]
11. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.
Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Edouard C; Vignon C; Mathieu L; Trechsel U
Lancet; 1979 Sep; 2(8141):489-92. PubMed ID: 90215
[TBL] [Abstract][Full Text] [Related]
12. Use of dichloromethylene diphosphonate in metastatic bone disease.
Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
[TBL] [Abstract][Full Text] [Related]
13. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
[TBL] [Abstract][Full Text] [Related]
14. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
[TBL] [Abstract][Full Text] [Related]
15. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications.
Clemens MR; Fessele K; Heim ME
Ann Hematol; 1993 Mar; 66(3):141-6. PubMed ID: 8471660
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism.
Elomaa I; Blomqvist C; Porkka L; Holmström T; Laine H
Cancer Treat Rep; 1984 Apr; 68(4):655-7. PubMed ID: 6231989
[TBL] [Abstract][Full Text] [Related]
18. The use of clodronate in multiple myeloma.
Delmas PD
Bone; 1991; 12 Suppl 1():S31-4. PubMed ID: 1835398
[TBL] [Abstract][Full Text] [Related]
19. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism.
Shane E; Baquiran DC; Bilezikian JP
Ann Intern Med; 1981 Jul; 95(1):23-7. PubMed ID: 6264825
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man.
McCloskey EV; Yates AJ; Beneton MN; Galloway J; Harris S; Kanis JA
Bone; 1987; 8 Suppl 1():S35-41. PubMed ID: 2825741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
